Astragalus Membranaceus Inhibits Peritoneal Fibrosis Via Monocyte Chemoattractant Protein (MCP)-1 and the Transforming Growth Factor-β1 (TGF-β1) Pathway in Rats Submitted to Peritoneal Dialysis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2014 Jul 24

PMID 25054320

Citations 22

Authors

Zhenghong Li

Lu Zhang

Weiming He

Changle Zhu

Jinsong Yang

Meixiao Sheng

Affiliations

Soon will be listed here.

Abstract

Inflammation and transforming growth factor-β1 (TGF-β1) contribute to the development of peritoneal fibrosis (PF), which is associated with peritoneal dialysis (PD). Astragalus membranaceus (Astragalus) has anti-inflammatory and anti-fibrotic effects in many diseases. The goal of this study was to determine the anti-fibrotic effects of Astragalus on the PF response to PD. A rat model of PD was induced using standard PD fluid, and PF was verified by HE and Masson's staining, as well as through the expression of fibroblast surface protein (FSP) and collagen III. The expression levels of monocyte chemoattractant protein (MCP)-1, F4/80 (macrophage/monocyte marker in rat), TGF-β1 and the downstream proteins phospho-SMAD 2/3 in dialyzed peritoneal tissue treated with or without Astragalus was evaluated using immunohistochemistry analysis. Overall correlations between MCP-1 and TGF-β1 staining were analyzed using both the Spearman and Pearson methods. The results showed that Astragalus could inhibit the recruitment and activation of monocytes/macrophages, thereby reducing the production of TGF-β1 in the dialyzed peritoneal membrane. PF was also significantly decreased following treatment with Astragalus. MCP-1 expression had a strong positive correlation with TGF-β1 sensitivity, suggesting that the anti-fibrotic function of Astragalus was mediated by MCP-1 and the TGF-β1 pathway. Our results indicate that Astragalus could be a useful agent against PD-induced PF.

Citing Articles

Mechanisms underlying the involvement of peritoneal macrophages in the pathogenesis and novel therapeutic strategies for dialysis-induced peritoneal fibrosis.

Wang Y, Zhang Y, Ma M, Zhuang X, Lu Y, Miao L Front Immunol. 2025; 15:1507265.

PMID: 39749340 PMC: 11693514. DOI: 10.3389/fimmu.2024.1507265.

Astragalus membranaceus and its monomers treat peritoneal fibrosis and related muscle atrophy through the AR/TGF-β1 pathway.

Sheng L, Sun J, Huang L, Yu M, Meng X, Shan Y Front Pharmacol. 2024; 15:1418485.

PMID: 39239655 PMC: 11374727. DOI: 10.3389/fphar.2024.1418485.

Treatment of peritoneal fibrosis: Therapeutic prospects of bioactive Agents from Astragalus membranaceus.

Huang Y, Chu C, Mai Y, Zhao Y, Cao L, Ji S Front Pharmacol. 2024; 15:1347234.

PMID: 38835665 PMC: 11148558. DOI: 10.3389/fphar.2024.1347234.

Sterile inflammation of peritoneal membrane caused by peritoneal dialysis: focus on the communication between immune cells and peritoneal stroma.

Su H, Zou R, Su J, Chen X, Yang H, An N Front Immunol. 2024; 15:1387292.

PMID: 38779674 PMC: 11109381. DOI: 10.3389/fimmu.2024.1387292.

Jian-Pi-Yi-Shen formula alleviates renal fibrosis by restoring NAD+ biosynthesis and .

Gao L, Huang X, Deng R, Wu S, Peng Y, Xiong G Aging (Albany NY). 2023; 16(1):106-128.

PMID: 38157259 PMC: 10817388. DOI: 10.18632/aging.205352.

References

He X, Shu J, Xu L, Lu C, Lu A . Inhibitory effect of Astragalus polysaccharides on lipopolysaccharide-induced TNF-a and IL-1β production in THP-1 cells. Molecules. 2012; 17(3):3155-64. PMC: 6268450. DOI: 10.3390/molecules17033155. View

Xu J, Lin S, Chen J, Miao Y, Taffet G, Entman M . CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis. Am J Physiol Heart Circ Physiol. 2011; 301(2):H538-47. PMC: 3154672. DOI: 10.1152/ajpheart.01114.2010. View

He S, Yang Y, Liu X, Huang W, Yang S, Zhang X . Compound Astragalus and Salvia miltiorrhiza extract inhibits cell proliferation, invasion and collagen synthesis in keloid fibroblasts by mediating transforming growth factor-β / Smad pathway. Br J Dermatol. 2011; 166(3):564-74. DOI: 10.1111/j.1365-2133.2011.10674.x. View

Kim B, Oh I, Kim J, Jeon J, Jeon B, Shin J . Anti-inflammatory activity of compounds isolated from Astragalus sinicus L. in cytokine-induced keratinocytes and skin. Exp Mol Med. 2014; 46:e87. PMC: 3972784. DOI: 10.1038/emm.2013.157. View

Grassmann A, Gioberge S, Moeller S, Brown G . ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005; 20(12):2587-93. DOI: 10.1093/ndt/gfi159. View

Nalbantsoy A, Nesil T, Yilmaz-Dilsiz O, Aksu G, Khan S, Bedir E . Evaluation of the immunomodulatory properties in mice and in vitro anti-inflammatory activity of cycloartane type saponins from Astragalus species. J Ethnopharmacol. 2011; 139(2):574-81. DOI: 10.1016/j.jep.2011.11.053. View

Gao J, Feng L, Huang Y, Li P, Xu D, Li J . Total glucosides of Danggui Buxue Tang attenuates bleomycin-induced pulmonary fibrosis via inhibition of extracellular matrix remodelling. J Pharm Pharmacol. 2012; 64(6):811-20. DOI: 10.1111/j.2042-7158.2012.01490.x. View

Burkart J . Peritoneal dialysis should be considered as the first line of renal replacement therapy for most ESRD patients. Blood Purif. 2001; 19(2):179-84. DOI: 10.1159/000046937. View

Lai P, Chan J, Wu S, Cheng L, Ho G, Lau C . Anti-inflammatory activities of an active fraction isolated from the root of Astragalus membranaceus in RAW 264.7 macrophages. Phytother Res. 2013; 28(3):395-404. DOI: 10.1002/ptr.5002. View

10.

Margetts P, Bonniaud P, Liu L, Hoff C, Holmes C, West-Mays J . Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol. 2004; 16(2):425-36. DOI: 10.1681/ASN.2004060436. View

11.

Huang W, Liang Y, Tang L, Ding Y, Wang X . Antioxidant and anti-inflammatory effects of Astragalus polysaccharide on EA.hy926 cells. Exp Ther Med. 2013; 6(1):199-203. PMC: 3735908. DOI: 10.3892/etm.2013.1074. View

12.

Sullivan D, Ferris M, Nguyen H, Abboud E, Brody A . TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J Cell Mol Med. 2010; 13(8B):1866-76. PMC: 2855747. DOI: 10.1111/j.1582-4934.2009.00647.x. View

13.

Strippoli R, Benedicto I, Lozano M, Cerezo A, Lopez-Cabrera M, Del Pozo M . Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-kappaB/Snail1 pathway. Dis Model Mech. 2008; 1(4-5):264-74. PMC: 2590814. DOI: 10.1242/dmm.001321. View

14.

Bradley J, Hamilton D, McWhinnie D, Briggs J, Junor B . Sclerosing peritonitis after CAPD. Lancet. 1983; 2(8349):572-3. DOI: 10.1016/s0140-6736(83)90600-1. View

15.

Musi B, Braide M, Carlsson O, Wieslander A, Albrektsson A, Ketteler M . Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats. Perit Dial Int. 2004; 24(1):37-47. View

16.

Du J, Sun M, Du G, Li F, Liu C, Mu Y . Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway. BMC Complement Altern Med. 2012; 12:33. PMC: 3419610. DOI: 10.1186/1472-6882-12-33. View

17.

Devuyst O, Margetts P, Topley N . The pathophysiology of the peritoneal membrane. J Am Soc Nephrol. 2010; 21(7):1077-85. DOI: 10.1681/ASN.2009070694. View

18.

Oreopoulos D, Khanna R, Wu G . Sclerosing obstructive peritonitis after CAPD. Lancet. 1983; 2(8346):409. DOI: 10.1016/s0140-6736(83)90382-3. View

19.

Strippoli R, Benedicto I, Lozano M, Pellinen T, Sandoval P, Lopez-Cabrera M . Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells. PLoS One. 2012; 7(2):e31492. PMC: 3288041. DOI: 10.1371/journal.pone.0031492. View

20.

Margetts P, Oh K, Kolb M . Transforming growth factor-beta: importance in long-term peritoneal membrane changes. Perit Dial Int. 2005; 25 Suppl 3:S15-7. View